Next 10 |
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference PR Newswire Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NE...
Trevi Therapeutics to Participate in Upcoming April Events PR Newswire NEW HAVEN, Conn. , April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio!...
2024-04-02 16:43:27 ET Gainers: Sight Sciences ( SGHT ) +19% . Zapata Computing Holdings ( ZPTA ) +9% . Cal-Maine Foods ( CALM ) +6% . Vanda Pharmaceuticals ( VNDA ) +5% . iHeartMedia ( IHRT ) +5% . Losers: Ac...
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team PR Newswire Margaret Garin , MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn. , April 2, 2024 /PRNewswir...
2024-03-20 18:21:10 ET Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Conference Call March 20, 2024 04:30 PM ET Company Participants Jennifer Good - President & CEO Lisa Delfini - CFO David Clark - Chief Medical Officer Conference Call Participants ...
2024-03-20 16:52:24 ET Gainers: Micron Technology ( MU ) +13% . Accuray ( ARAY ) +5% . Western Digital Corporation ( WDC ) +4% . AXT ( AXTI ) +4% . Intapp ( INTA ) +3% . Losers: Five Below ( FIVE ) -13% . ...
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressi...
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 PR Newswire Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. , March 13, 2024 /PRNewswire/ -- Trevi T...
Trevi Therapeutics to Participate in Upcoming March Events PR Newswire NEW HAVEN, Conn. , Feb. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference PR Newswire Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NE...
Trevi Therapeutics to Participate in Upcoming April Events PR Newswire NEW HAVEN, Conn. , April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio!...
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team PR Newswire Margaret Garin , MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn. , April 2, 2024 /PRNewswir...